ClinicalTrials.gg
RecruitingNCT07349537Updated Sep 17, 2026

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

A Phase 1 interventional study of RMC-5127 and daraxonrasib in Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) and Pancreatic Adenocarcinoma, sponsored by Revolution Medicines, Inc.. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Revolution Medicines, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
574
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. — 8 open to participants now, 9 under way, 2 of them phase 3. Carcinoma, Non-Small-Cell Lung · Revolution Medicines, Inc..

Planned enrollment
5th of 13
574 · median 430
Started
2026
with 2 others
Phase 1
5 of 13
2 open now
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., this one is the 5th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 in phase 1, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc. are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Non-Small-Cell Lung by Revolution Medicines, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

Read the detailed description

This is an open-label, multicenter, Phase 1/1b study of RMC-5127 in adults with advanced KRAS G12V-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of three arms: RMC-5127 monotherapy arm, RMC-5127 plus daraxonrasib combination arm, and RMC-5127 plus cetuximab combination arm. All arms consist of two parts: Part 1- dose exploration and Part 2- dose expansion. Both parts of the monotherapy arm may include Food Effect Cohorts.

03

Conditions studied

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Adenocarcinoma
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • PDAC
  • CRC
  • NSCLC
  • Pancreatic Cancer
  • Lung Cancer (NSCLC)
  • Advanced Solid Tumors

Keywords

  • Advanced Solid Tumors
  • Pancreatic Cancer
  • Pancreatic Ductal Adenocarcinoma
  • PDAC
  • Colorectal Cancer
  • CRC
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • NSCLC
  • RAS
  • KRAS
  • RAS Mutation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old and has provided .
  • (ECOG) performance status of 0 or 1.
  • documented, locally advanced or KRAS G12V-mutated solid tumor .
  • Received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage.
  • Measurable per v1.1
  • Adequate organ function (bone marrow, liver, kidney, coagulation).
  • Able to take oral medications.

Exclusion criteria

Exclusion Criteria:

  • Primary central nervous system (CNS) tumors
  • Prior therapy with KRAS G12V inhibitor or direct RAS-targeted therapy (eg. degraders and/or inhibitors).
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery within 28 days prior to receiving study drug(s).
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
574 participants (estimated)

Study arms

  • Experimental
    Arm A: RMC-5127 Monotherapy

    Dose Escalation and Dose Expansion

    Drug: RMC-5127

  • Experimental
    Arm B: RMC-5127 + Daraxonrasib Combination

    Dose Escalation and Dose Expansion

    Drug: RMC-5127 · Drug: daraxonrasib

  • Experimental
    Arm C: RMC-5127 + Cetuximab Combination

    Dose Escalation and Dose Expansion

    Drug: RMC-5127 · Drug: cetuximab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with adverse events (AEs)

    Number of patients with AEs as assessed by Common Terminology Criteria for Adverse Events CTCAE v5

    Time frame: Up to approximately 3 years

  2. Changes in vital signs

    Number of patients with changes from baseline in vital signs

    Time frame: Up to approximately 3 years

  3. Changes in electrocardiogram (ECG) test values

    Number of patients with changes from baseline in ECG test values

    Time frame: Up to approximately 3 years

  4. Changes in clinical laboratory test values

    Number of patients with changes from baseline in clinical laboratory test values

    Time frame: Up to approximately 3 years

  5. Dose Limiting Toxicities

    Number of patients with dose limiting toxicities

    Time frame: Up to 28 days

Secondary outcomes

  1. Cmax concentrations of RMC-5127 and daraxonrasib

    Maximum blood concentration (Cmax) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and Cmax of daraxonrasib in combination with RMC-5127 over time as applicable

    Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)

  2. Tmax concentration of RMC-5127 and daraxonrasib

    Time to reach maximum blood concentration (Tmax) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and Tmax of daraxonrasib in combination with RMC-5127 over time as applicable

    Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)

  3. AUC concentrations of RMC-5127 and daraxonrasib

    Area under the blood concentration time curve (AUC) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and AUC of daraxonrasib in combination with RMC-5127 over time as applicable

    Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)

  4. Ratio of accumulation of RMC-5127

    Ratio of accumulation of RMC-5127 from a single dose to steady state with repeated dosing as monotherapy and in combination with darabxrasib or cetuximab over time as applicable

    Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)

  5. Half-Life of RMC-5127 and daraxonrasib

    Elimination Half-Life (t1/2) of RMC-5127 as monotherapy and in combination with daraxonrasib or cetuximab, and t1/2 of daraxonrasib in combination with RMC-5127 over time as applicable

    Time frame: Up to Cycle 5 Day 1 (each cycle is up to 28 days)

  6. Objective Response Rate (ORR)

    ORR per response evaluation criteria in solid tumors (RECIST) v1.1

    Time frame: Up to approximately 3 years

  7. Duration of Response (DOR)

    DOR per RECIST v1.1

    Time frame: Up to approximately 3 years

07

Study locations

9 of 9 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2028, 27 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2026
First posted
Jan 16, 2026
StartActual
Jan 8, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Oct 2028
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07349537
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jan 8, 2026
Primary completion
Apr 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 17, 2026

Study contacts

Revolution Medicines Study Director
Contact
medinfo@revmed.com
1-844-2-REVMED

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion